<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Futura Medical Plc — News on 6ix</title>
<link>https://6ix.com/company/futura-medical-plc</link>
<description>Latest news and press releases for Futura Medical Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/futura-medical-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d57eefbeedb30cb6f89c30.webp</url>
<title>Futura Medical Plc</title>
<link>https://6ix.com/company/futura-medical-plc</link>
</image>
<item>
<title>Unaudited Results for the Year Ended 31 Dec 2025</title>
<link>https://6ix.com/company/futura-medical-plc/news/unaudited-results-for-the-year-ended-31-dec-2025</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/unaudited-results-for-the-year-ended-31-dec-2025</guid>
<pubDate>Wed, 29 Apr 2026 06:00:00 GMT</pubDate>
<description>Futura Medical PLC reported unaudited results for the year ended 31 December 2025, with revenue falling to £1.7 million from £13.9 million in the prior year, alongside an operating loss of £9.1 million compared to a £1.2 million profit. The company experienced challenges with Eroxon® sales, leading to a strategic review and a shift towards a hybrid R&D and commercial model. Despite the financial downturn, development progressed on Eroxon® Intense and the WSD4000 female sexual health portfolio, w</description>
</item>
<item>
<title>Notice of Results & Investor Presentation</title>
<link>https://6ix.com/company/futura-medical-plc/news/notice-of-results-and-investor-presentation-159</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/notice-of-results-and-investor-presentation-159</guid>
<pubDate>Mon, 20 Apr 2026 06:00:00 GMT</pubDate>
<description>Futura Medical plc announced that it will release its full year results for the year ended 31 December 2025 on Wednesday 29 April, with management hosting a webinar presentation on the same day at 10:00 BST via the Investor Meet Company platform. The company, known for its sexual health products like Eroxon®, is inviting existing and potential shareholders to attend the presentation, where questions can be submitted in advance or during the live event.
Disclaimer*</description>
</item>
<item>
<title>Positive Eroxon® & Eroxon® “Intense” HUT results</title>
<link>https://6ix.com/company/futura-medical-plc/news/positive-eroxonr-and-eroxonr-intense-hut-results</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/positive-eroxonr-and-eroxonr-intense-hut-results</guid>
<pubDate>Mon, 23 Mar 2026 07:00:00 GMT</pubDate>
<description>Futura Medical plc has announced positive results from a Home User Test for its Eroxon® product and a new prototype, Eroxon® 'Intense', showing statistically significant greater sensorial effect in the first two minutes for the Intense formula. In the study of 223 subjects with mild to moderate erectile dysfunction, both formulations demonstrated high efficacy, with subjects reporting satisfaction with erection hardness in 70-71% of encounters and sufficient duration for intercourse in 84-85% of</description>
</item>
<item>
<title>Formal Grant of US Patent</title>
<link>https://6ix.com/company/futura-medical-plc/news/formal-grant-of-us-patent</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/formal-grant-of-us-patent</guid>
<pubDate>Wed, 18 Mar 2026 07:00:00 GMT</pubDate>
<description>Futura Medical plc has been granted a US continuation patent, No. 12,576,152, by the US Patent Office, providing protection for Eroxon® and the women's product WSD4000 until 2040. This patent grant is expected to trigger a US$2.5 million milestone payment from Haleon under their existing licence agreement, which is a significant positive development for the company.
Disclaimer*</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/futura-medical-plc/news/holdings-in-company-1246</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/holdings-in-company-1246</guid>
<pubDate>Tue, 17 Mar 2026 11:37:00 GMT</pubDate>
<description>Mr R McAlpine has acquired a holding in Futura Medical plc, resulting in a total of 20,000,000 voting rights, which represents 3.44% of the total voting rights. This acquisition occurred on 4 December 2025, and the notification was made on 17 March 2026. Mr McAlpine is not controlled by any other entity and does not control any other undertakings holding an interest in Futura Medical plc.
Disclaimer*</description>
</item>
<item>
<title>Patent notice of allowance granted for the US</title>
<link>https://6ix.com/company/futura-medical-plc/news/patent-notice-of-allowance-granted-for-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/patent-notice-of-allowance-granted-for-the-us</guid>
<pubDate>Thu, 05 Feb 2026 07:00:00 GMT</pubDate>
<description>Futura Medical PLC has received notice of allowance for a US continuation patent for MED3000 (Eroxon), extending protection for Eroxon and the women's product WSD4000 until 2040. This patent allowance is expected to trigger a US$2.5 million milestone payment from Haleon, bolstering the company's cash runway. The new patent's formulation claims enhance Futura's competitive position in the significant US erectile dysfunction market and protect its development product WSD4000. This adds to existing</description>
</item>
<item>
<title>Trading Update</title>
<link>https://6ix.com/company/futura-medical-plc/news/trading-update-826</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/trading-update-826</guid>
<pubDate>Wed, 04 Feb 2026 07:00:00 GMT</pubDate>
<description>Futura Medical PLC anticipates FY25 revenue of £1.7 million, exceeding previous guidance, with net cash standing at £3.4 million following a November 2025 fundraise. The company expects a US$2.5 million milestone payment from Haleon in H1 2026, contingent on a US patent for Eroxon, and anticipates a £0.3 million tax credit refund for FY2025. These combined resources are projected to provide a cash runway until December 2026, aligning with prior statements. A strategic review of the business is o</description>
</item>
<item>
<title>Results of WSD4000 Early Feasibility Study</title>
<link>https://6ix.com/company/futura-medical-plc/news/results-of-wsd4000-early-feasibility-study</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/results-of-wsd4000-early-feasibility-study</guid>
<pubDate>Mon, 12 Jan 2026 07:00:00 GMT</pubDate>
<description>Futura Medical plc has announced positive results from its WSD4000 Early Feasibility Study involving 12 women with sexual dysfunction, showing a statistically significant improvement in overall sexual function by 6.35 units on the FSFI scale, exceeding the minimal clinically important difference of 4 units. The study also demonstrated significant improvements in arousal, lubrication, pain, orgasm, and satisfaction, with 64.2% of uses reporting moderate or high desire and 91.1% reporting conditio</description>
</item>
<item>
<title>Notification of major holdings</title>
<link>https://6ix.com/company/futura-medical-plc/news/notification-of-major-holdings-223</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/notification-of-major-holdings-223</guid>
<pubDate>Wed, 07 Jan 2026 16:34:00 GMT</pubDate>
<description>Spreadex LTD has notified Futura Medical PLC of a change in its major holding, with its total voting rights now standing at 3.923200%, down from a previous holding of 4.436800%. This change is due to an acquisition or disposal of financial instruments, specifically a decrease in its holdings through CFDs/Spread Bets, resulting in a total of 22,806,403 voting rights.
Disclaimer*</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/futura-medical-plc/news/total-voting-rights-927</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/total-voting-rights-927</guid>
<pubDate>Wed, 31 Dec 2025 07:00:00 GMT</pubDate>
<description>Futura Medical plc has announced its total issued share capital as of December 31, 2025, stands at 581,327,755 Ordinary Shares, with no shares currently held in treasury, meaning the total number of voting rights is also 581,327,755. This figure will serve as the denominator for shareholders calculating their notification requirements under the FCA's Disclosure and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>Patent notice of allowance granted for China</title>
<link>https://6ix.com/company/futura-medical-plc/news/patent-notice-of-allowance-granted-for-china</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/patent-notice-of-allowance-granted-for-china</guid>
<pubDate>Wed, 10 Dec 2025 07:00:00 GMT</pubDate>
<description>Futura Medical PLC has received notice of patent allowance for its Eroxon product in China, securing protection until 2040 and enhancing its competitive position in a market with an estimated 50% prevalence of erectile dysfunction among 700 million adult males. This allowance adds to existing protection in Europe, Hong Kong, Taiwan, and the US, with further applications pending and a divisional patent planned for early 2026. The company is actively seeking partners in China to leverage this sign</description>
</item>
<item>
<title>Block Listing Six Monthly Return</title>
<link>https://6ix.com/company/futura-medical-plc/news/block-listing-six-monthly-return-192</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/block-listing-six-monthly-return-192</guid>
<pubDate>Tue, 09 Dec 2025 15:59:00 GMT</pubDate>
<description>Futura Medical plc has provided a block listing six-monthly return detailing its share option schemes. The company reported a balance of 16,237,570 unallotted securities across its Unapproved Share Option Scheme, Unapproved Share Incentive Scheme, EMI Share Option Scheme, and LTIP Scheme as of December 8, 2025. During the period from June 1, 2025, to December 8, 2025, no securities were issued or allotted under the Unapproved Share Option Scheme, Unapproved Share Incentive Scheme, or EMI Share O</description>
</item>
<item>
<title>Directors' / PDMR dealing</title>
<link>https://6ix.com/company/futura-medical-plc/news/directors-pdmr-dealing</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/directors-pdmr-dealing</guid>
<pubDate>Mon, 08 Dec 2025 12:18:00 GMT</pubDate>
<description>Futura Medical plc announced that its Directors and persons closely associated subscribed for an aggregate of 6,000,000 Ordinary Shares at 1 pence per share, totaling £60,000, as part of a fundraise. Specifically, Alex Duggan subscribed for 5,000,000 shares, Angela Hildreth for 500,000 shares, and Ken James for 500,000 shares. These transactions, which occurred on December 4, 2025, represent a direct investment by key management personnel into the company, potentially signaling confidence in its</description>
</item>
<item>
<title>Board change</title>
<link>https://6ix.com/company/futura-medical-plc/news/board-change-243</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/board-change-243</guid>
<pubDate>Wed, 03 Dec 2025 07:00:00 GMT</pubDate>
<description>Futura Medical plc announces a board change with Harmesh Suniara stepping down as Non-Executive Director with immediate effect, following resolutions for a placing and subscription that will significantly reduce Lombard Odier Asset Management's shareholding. The company expresses gratitude for his guidance, particularly ahead of the fundraise which provides a secure financial footing. Futura Medical is now focused on completing its strategic review in Q1 FY26 and progressing the development of E</description>
</item>
<item>
<title>Result of General Meeting and Total Voting Rights</title>
<link>https://6ix.com/company/futura-medical-plc/news/result-of-general-meeting-and-total-voting-rights-47</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/result-of-general-meeting-and-total-voting-rights-47</guid>
<pubDate>Tue, 02 Dec 2025 11:27:00 GMT</pubDate>
<description>Futura Medical PLC announced that all resolutions presented at its General Meeting were passed with overwhelming support, with over 99.23% of votes cast in favour of each resolution, paving the way for the completion of its placing and subscription fundraise. Following the admission of 13,200,000 Subscription Shares and 231,800,000 Conditional Placing Shares to AIM, expected around December 4, 2025, the company's total issued ordinary shares will be 581,120,659. This significant capital raise an</description>
</item>
<item>
<title>PCA Dealing</title>
<link>https://6ix.com/company/futura-medical-plc/news/pca-dealing-10</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/pca-dealing-10</guid>
<pubDate>Fri, 14 Nov 2025 16:40:00 GMT</pubDate>
<description>Futura Medical plc announced that Lombard Odier Asset Management (Europe) Limited, a fund associated with Non-Executive Director Harmesh Suniara, sold 4,441,678 ordinary shares at 1.5 pence per share on November 13, 2025. Following this transaction, the fund now holds 82,339,520 ordinary shares, representing 26.90% of the company's issued share capital.
Disclaimer*</description>
</item>
<item>
<title>Posting of Circular and Notice of GM</title>
<link>https://6ix.com/company/futura-medical-plc/news/posting-of-circular-and-notice-of-gm-8</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/posting-of-circular-and-notice-of-gm-8</guid>
<pubDate>Thu, 13 Nov 2025 16:35:00 GMT</pubDate>
<description>Futura Medical plc has announced the posting of a Circular and Notice of General Meeting to shareholders following its £2.75 million fundraise. The General Meeting is scheduled for December 2, 2025, at the company's registered office, where voting results on all resolutions will be announced via RNS and published on the company's website.
Disclaimer*</description>
</item>
<item>
<title>Results for the six months ended 30 June 2025</title>
<link>https://6ix.com/company/futura-medical-plc/news/results-for-the-six-months-ended-30-june-2025-8</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/results-for-the-six-months-ended-30-june-2025-8</guid>
<pubDate>Tue, 30 Sep 2025 06:00:00 GMT</pubDate>
<description>Futura Medical PLC reported revenue of £1.0 million for the six months ended June 30, 2025, a decrease from £7.0 million in HY24, reflecting slower in-market sales of Eroxon. Underlying gross profit was £0.73 million, excluding a £0.49 million exceptional provision for potential inventory obsolescence. The company experienced a loss after tax of £6.59 million, which included £3.6 million of exceptional items for impairment of plant and equipment and a £0.65 million non-cash charge for share-base</description>
</item>
<item>
<title>Notice of Results and Investor Presentation</title>
<link>https://6ix.com/company/futura-medical-plc/news/notice-of-results-and-investor-presentation-160</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/notice-of-results-and-investor-presentation-160</guid>
<pubDate>Fri, 26 Sep 2025 11:11:00 GMT</pubDate>
<description>Futura Medical PLC will release its interim results for the six months ended June 30, 2025, on Tuesday, September 30, 2025. Management will host a webinar via the Investor Meet Company platform on September 30, 2025, at 09.30am BST to discuss the results. The presentation is open to all existing and potential shareholders, who can submit questions in advance until 9.00am BST the day before or during the live presentation. Interested parties can register for the presentation through a provided li</description>
</item>
<item>
<title>Trading, Business and Strategic Review Update</title>
<link>https://6ix.com/company/futura-medical-plc/news/trading-business-and-strategic-review-update</link>
<guid isPermaLink="true">https://6ix.com/company/futura-medical-plc/news/trading-business-and-strategic-review-update</guid>
<pubDate>Fri, 19 Sep 2025 06:00:00 GMT</pubDate>
<description>Futura Medical anticipates revenue for the year ending December 31, 2025, to be materially below expectations, now projected to be between £1.3 million and £1.4 million. This is due to slower than anticipated in-market sales of Eroxon across all markets, especially in the USA, leading to lower replenishment sales. Furthermore, a $2.5 million payment from Haleon, contingent on the granting of a US patent for Eroxon, is now expected in H1 2026. As of August 2025, cash and cash equivalents stood at</description>
</item>
</channel>
</rss>